Clinical Trial Disappointment for This Pharmaceutical Giant

More than 10 million people around the world suffer from Parkinson's disease, according to the Parkinson's Disease Foundation. Unfortunately, pharmaceutical company Merck (NYSE: MRK  ) announced last week that it will halt the development of an experimental drug for this indication because of disappointing clinical data. Does Merck have other drugs in development for this disease? Are smaller biotechs making progress in this space? Health-care analyst Max Macaluso discusses these questions in the following video.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.



Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2466409, ~/Articles/ArticleHandler.aspx, 4/17/2014 2:34:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 16,435.44 10.59 0.06%
S&P 500 1,868.76 6.45 0.35%
NASD 4,105.65 19.43 0.48%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/17/2014 2:07 PM
MRK $56.56 Up +0.30 +0.52%
Merck & Co., Inc. CAPS Rating: ***
GSK $52.68 Down -0.14 -0.27%
GlaxoSmithKline CAPS Rating: ***
IPXL $23.94 Down -0.37 -1.52%
Impax Laboratories… CAPS Rating: ***
LGND $64.36 Up +1.46 +2.31%
Ligand Pharmaceuti… CAPS Rating: **

Advertisement